Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM7 | Q14831 | 13/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | OGA | O60502 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31483731 | 1.00 | GRM7 (0.50) | GRM7CRBNOGAALDH1A1HPGD | |
| SCHEMBL20836342 | 0.86 | GRM7 (0.43) | GRM7 | |
| SCHEMBL20836475 | 0.74 | GRM7 (0.57) | GRM7CRBNGABRA1GABRG2GABRB3 | |
| SCHEMBL31483702 | 0.74 | GRM7 (0.57) | GRM7CRBNGABRA1GABRG2GABRB3 | |
| SCHEMBL22257259 | 0.71 | GRM7 (0.71) | GRM7 | |
| SCHEMBL29019285 | 0.70 | ALDH1A1 (0.35) | CRBNALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL29830882 | 0.68 | OGA (0.35) | CRBNOGAALDH1A1HPGDHSD17B10 | |
| SCHEMBL31483616 | 0.67 | GRM7 (1.00) | GRM7 | |
| SCHEMBL20836301 | 0.67 | GRM7 (1.00) | GRM7 | |
| SCHEMBL20836453 | 0.66 | GRM7 (0.81) | GRM7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257049-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | PRAGMA THERAPEUTICS (FR) | 2025-08-14 | — | — | US | disclosed |
| US-11414395-B2 | Heterocyclic compounds as modulators of mGluR7 | PRAGMA THERAPEUTICS (FR) | 2022-08-16 | — | — | US | disclosed |
| US-20200231563-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | PRAGMA THERAPEUTICS (FR) | 2020-07-23 | — | — | US | disclosed |
| CN-111148744-A | Novel heterocyclic compounds as MGLUR7 modulators | 布拉格玛治疗公司 | 2020-05-12 | — | — | CN | disclosed |
| EP-3459939-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | Pragma Therapeutics (FR) | 2019-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257049-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | GRM7, GRM1, GRM2 | GRM7 1/4885CRBN 3484/4885OGA 3427/4885 |
| US-20200231563-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | GRM7, GRM1, GRM3 | GRM7 1/4885CRBN 3179/4885OGA 3617/4885 |
| US-11414395-B2 | Heterocyclic compounds as modulators of mGluR7 | GRM7, GRM1, GRM3 | GRM7 1/4885CRBN 3087/4885OGA 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.